once-daily

Lixiana®

edoxaban tosylate monohydrate tablets

In atrial fibrillation

Clear dosage selection criteria

60 mg once daily

RECOMMENDED DOSE FOR STROKE PREVENTION IN AF*

30 mg once daily

FOR PATIENTS MEETING ONE OR MORE OF THE FOLLOWING CRITERIA:

Can now be prescribed for patients with severe renal impairment (CrCL 15–29 mL/min)

Moderate (CrCL 30–50 mL/min) **or severe** (CrCL 15–29 mL/min) **renal impairment†**

(not recommended in patients with end stage renal disease [CrCL < 15 mL/min] or on dialysis)

or

Low body weight

≤ 60 kg (132 lb.)

or

Concomitant use of P-gp inhibitors

such as cyclosporine, dronedarone, erythromycin, ketoconazole, and quinidine. Amiodarone and verapamil are exceptions.

Covered by provincial formulary! (Exception Drug Status)

Check your provincial listing for coverage criteria.

CrCL: creatinine clearance; P-gp: P-glycoprotein
*Consult the Product Monograph for complete dosing and administration information.
†Estimated CrCL should be determined in all patients prior to start of LIXIANA® treatment.

CrCL should be monitored at the beginning of the treatment in all patients and afterwards when clinically indicated. Plasma concentration of LIXIANA® is increased with the degree of renal impairment.

LIXIANA® (edoxaban) is indicated for prevention of stroke and systemic embolic events in patients with atrial fibrillation (AF), in whom anticoagulation is appropriate.

Comparison of recommended dosing of NOACs for use in the prevention of stroke and systemic embolic events in patients with AF

	Recommended dose	Frequency	Oral administration
LIXIANA® (edoxaban)*,[1]	**60 mg**	**1x** **Once daily**	**With or without food**
XARELTO® (rivaroxaban)*,[6]	**20 mg**	**1x** **Once daily**	**With food** (15 and 20 mg)
ELIQUIS® (apixaban)*,[7]	**5 mg**	**2x** **Twice daily** (10 mg total daily dose)	**With or without food**
PRADAXA® (dabigatran etexilate)*,[8]	**150 mg**	**2x** **Twice daily** (300 mg total daily dose)	**With or without food** PRADAXA® should be taken with a full glass of water. PRADAXA® should be taken with meals in patients with dyspepsia.†

Adapted from the LIXIANA®, XARELTO®, ELIQUIS®, and PRADAXA® Product Monographs. Trademarks are the property of their respective owners.
*Data from separate Product Monographs; comparative clinical significance unknown.
†Based on clinical judgment, treatment with a proton pump inhibitor may be considered in patients still experiencing dyspepsia despite taking PRADAXA® with or within 30 minutes after a meal.

Refer to the respective Product Monographs for complete dosing and administration information, including dose reductions, special populations, and drug interactions.

LIXIANA® should be taken regularly, as prescribed, to ensure optimal effectiveness. All temporary discontinuations should be avoided, unless medically indicated.

If a dose is missed, the dose must be taken as soon as possible on the same day. The dose should not be doubled to make up for the missed dose. Patients should return to their normal schedule the next day.

NOAC: non-vitamin K antagonist oral anticoagulant

Convenient once-daily dosing

DOSING FREQUENCY:
One-pill, once-daily dosing*,[1]

ORAL ADMINISTRATION:
Taken with or without food*,[1]

A manageable transition process

Recommendations for switching to LIXIANA®

Continued anticoagulant therapy is important for stroke prevention in patients with AF. There may be situations that warrant a change in anticoagulation therapy.

To transition from	Discontinue	Start LIXIANA®
NOACs (Oral anticoagulants other than vitamin K antagonists)	**Discontinue** the anticoagulant	**Start LIXIANA®** at the time of the next non-VKA dose
Vitamin K antagonists	**Discontinue** the VKA and **Track** the INR	**Start LIXIANA®** when the INR is ≤ 2.5

Refer to the Product Monograph for complete dosing and administration information, including complete recommendations for switching to and from LIXIANA®, dose reductions, special populations, and drug interactions.

Consult the Product Monograph at www.servier.ca/sites/default/files/webform/products/product-monograph-Lixiana-EN.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-363-6093 or by visiting www.servier.ca.

Please visit www.servier.ca/references/Lixiana_EN.pdf to access the reference list.

VKA: vitamin K antagonist; INR: international normalized ratio
*Consult the Product Monograph for complete dosing and administration information.

once-daily

Pr Lixiana®

edoxaban tosylate monohydrate tablets

COVERED BY PROVINCIAL FORMULARY!

Exception Drug Status

Check your provincial listing for coverage criteria.

Convenient once-daily dosing*

Taken with or without food

Clear dosage selection criteria

SERVIER

Daiichi-Sankyo

*Consult the Product Monograph for complete dosing and administration information.

Servier Canada Inc. 235, boulevard Armand-Frappier, Laval, QC H7V 4A7
www.servier.ca | 1-888-902-9700

REVIEWED BY PAAB

MEMBER OF INNOVATIVE MEDICINES CANADA